Cover Image
市場調查報告書

囊狀纖維化症:全球臨床實驗趨勢

Cystic Fibrosis Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 372541
出版日期 內容資訊 英文 467 Pages
訂單完成後即時交付
價格
Back to Top
囊狀纖維化症:全球臨床實驗趨勢 Cystic Fibrosis Global Clinical Trials Review, H2, 2017
出版日期: 2017年07月19日 內容資訊: 英文 467 Pages
簡介

本報告提供囊狀纖維化症治療藥相關臨床實驗的最新趨勢分析,彙整主要7個國家 (E7) 及新興7個國家 (G7) 的臨床實驗數量,受驗人數,有潛力的贊助商,參與臨床實驗的主要企業和機關,有潛力的藥劑等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:呼吸系統疾病治療藥臨床實驗上囊狀纖維化症的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:呼吸系統疾病治療藥臨床實驗上囊狀纖維化症的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

囊狀纖維化症治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4355CTIDB

GlobalData's clinical trial report, "Cystic Fibrosis Global Clinical Trials Review, H2, 2017" provides an overview of Cystic Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Cystic Fibrosis Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Latest Clinical Trials News on Cystic Fibrosis 36
  • Jul 12, 2017: Synspiras Novel Glycopolymer Improves Effectiveness of Antibiotics Against Drug-resistant Bacteria Associated with Cystic Fibrosis 36
  • Jul 10, 2017: Anthera Pharmaceuticals Announces Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network 36
  • Jun 29, 2017: Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis 37
  • Jun 20, 2017: Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference 37
  • Jun 13, 2017: Pharmaxis Announces Results of Pivotal Bronchitol Cystic Fibrosis Clinical Trial for US Market 38
  • Jun 09, 2017: Vertex Announces Nine Presentations of Data on ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) at the European Cystic Fibrosis Society Conference 38
  • Jun 08, 2017: Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference 40
  • Jun 08, 2017: Corbus Pharmaceuticals to Present Data from Phase 2 Study of Anabasum at the European Cystic Fibrosis Society 2017 Conference 40
  • Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial 41
  • Jun 07, 2017: Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference 41
  • Jun 07, 2017: Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs 42
  • Jun 07, 2017: Proteostasis Therapeutics Announces Update on Phase 1 Trial of PTI-808, CFTR potentiator 42
  • Jun 07, 2017: Proteostasis Therapeutics Announces Clinical Development Update on Cystic Fibrosis Drug Candidate PTI-801 43
  • Jun 05, 2017: Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA 43
  • Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis 43
  • May 24, 2017: Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference 43
  • May 23, 2017: Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference 44
  • May 17, 2017: Celtaxsys Announces Full Enrollment of Its Landmark EMPIRE-CF Phase 2b Clinical Trial Assessing the Potential of Novel Anti-inflammatory Investigational Therapy, Oral Acebilustat, to Preserve Lung Function in CF Patients 44
  • May 16, 2017: Spyryx Biosciences to Present at American Thoracic Society International Conference May 19- 24, 2017, Washington, DC 45
  • Apr 19, 2017: Laurent Pharmaceuticals Receives FDA and Health Canada Clearance to Initiate APPLAUD Phase 2 Clinical Study of LAU-7b for the Treatment of Cystic Fibrosis 45
  • Clinical Trial Profile Snapshots 47

Appendix 465

  • Abbreviations 465
  • Definitions 465
  • Research Methodology 466
  • Secondary Research 466
  • About GlobalData 467
  • Contact Us 467
  • Source 467

List of Tables

List of Tables

  • Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
  • Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017* 16
  • Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017* 20
  • Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2017* 24
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
  • Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 30
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35

List of Figures

List of Figures

  • Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
  • Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2017* 16
  • Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2017* 20
  • Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
  • Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 28
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 29
  • Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 30
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
  • Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 35
  • GlobalData Methodology 466
Back to Top